ZUH:CA:TSX-BMO Equal Weight US Health Care (CAD Hedged) (CAD)

ETF | Sector Equity |

Last Closing

CAD 73.19

Change

+0.36 (+0.49)%

Market Cap

CAD 0.27B

Volume

5.21K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Sector Equity

Symbol Name Price(Change) Market Cap
TEC:CA TD Global Technology Leaders I..

+0.14 (+0.35%)

CAD 2.88B
TEC:CA TD Global Technology Leaders I..

+0.14 (+0.35%)

CAD 2.88B
ZWU:CA BMO Covered Call Utilities ETF

N/A

CAD 1.94B
ZWU:CA BMO Covered Call Utilities ETF

N/A

CAD 1.94B
XHC:CA iShares Global Healthcare (CAD..

+0.21 (+0.28%)

CAD 0.65B
XHC:CA iShares Global Healthcare (CAD..

+0.21 (+0.28%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+0.49 (+0.85%)

CAD 0.65B
XIT:CA iShares S&P/TSX Capped Informa..

+0.49 (+0.85%)

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

N/A

CAD 0.65B
TXF:CA First Asset Tech Giants Covere..

N/A

CAD 0.65B

ETFs Containing ZUH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.30% 24% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.30% 21% F 34% F
Trailing 12 Months  
Capital Gain 13.97% 27% F 41% F
Dividend Return 0.79% 30% F 18% F
Total Return 14.75% 27% F 39% F
Trailing 5 Years  
Capital Gain 43.90% 39% F 65% D
Dividend Return 2.31% 20% F 10% F
Total Return 46.22% 27% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.87% N/A N/A 55% F
Dividend Return 5.25% N/A N/A 52% F
Total Return 0.38% N/A N/A 26% F
Risk Return Profile  
Volatility (Standard Deviation) 16.63% N/A N/A 71% C-
Risk Adjusted Return 31.56% N/A N/A 51% F
Market Capitalization 0.27B 69% C- 50% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.